Global Neuroblastoma Drugs Market Size study, by Type (Chemotherapy, Immunotherapy, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Online, Offline), and Regional Forecasts 2022-2032
Global Neuroblastoma Drugs Market is valued approximately USD 740 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2024-2032. Neuroblastoma is a cancer primarily occurring in young children below five years old, originating in nerve tissue specifically in the adrenal glands atop the kidneys. It emerges from immature nerve cells, called neuroblasts, known for its diverse symptoms and outcomes. These range from abdominal lumps, altered bowel patterns, bone discomfort, fatigue, to skin alterations, showcasing its varied presentation. Neuroblastoma drugs are medications tailored to combat neuroblastoma. It encompasses chemotherapy agents like cisplatin and etoposide, targeted therapies such as crizotinib targeting the ALK gene, immunotherapies like dinutuximab, differentiation agents like retinoic acid, and radiopharmaceuticals like I-131 MIBG. Treatment plans are individualized based on factors like the cancer stage and patient's health involving a combination of therapies designed by a team of specialists to optimize effectiveness. The rising shift towards personalized medicine and targeted therapies is a key trend for the Global Neuroblastoma Drugs Market. Drug developers are concentrating more on creating medications that specifically target genetic abnormalities or biological processes associated with neuroblastoma. This method reduces adverse effects and enhances patient outcomes by enabling more focused and efficient therapy.
In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.
The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.
Major market player included in this report are:
Recordati Group
Eli Lilly and Company
Bristol-Myers Squibb Company
Y-mabs Therapeutics, Inc.
MacroGenics Inc.
AstraZeneca plc
United Therapeutics Corporation
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Cellectar Biosciences, Inc.
The detailed segments and sub-segment of the market are explained below:
By Type
Chemotherapy
Immunotherapy
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Online
Offline
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
In addition, the key driving factors influencing the Neuroblastoma Drugs market include advancements in medical technology, leading to improved diagnosis and treatment options for neuroblastoma patients. Additionally, increased awareness about neuroblastoma and early detection initiatives contribute to the demand for neuroblastoma drugs. Moreover, ongoing research and development efforts focused on developing targeted therapies and immunotherapies further propel market growth. Pharmaceutical companies are heavily investing in research and development (R&D) of new neuroblastoma drugs to the unmet need for more effective treatments for this disease. As a result of this increased R&D activity, there are several new neuroblastoma drugs in the pipeline that have the potential to improve outcomes for patients. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare organizations foster innovation and the introduction of novel neuroblastoma drugs into the market, which are further presenting various growth prospects to the Global Neuroblastoma Drugs Market during the estimated period. However, adverse side effects associated with neuroblastoma drugs and stringent regulatory requirement for drug approvals are expected to stifle Global Neuroblastoma Drugs Market growth between 2022 and 2032.
The key regions considered for the global Neuroblastoma Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America held the dominant position in the neuroblastoma drugs market due to several factors such as rising availability of neuroblastoma drugs, supportive governmental initiatives, robust regulatory backing, and a well-established healthcare system. Moreover, the region benefits from the significant presence of key industry players that are actively engaged in strategic initiatives like product approvals and partnerships, contributing significantly to market expansion in North America. On the other hand, Asia Pacific is poised for rapid growth over the forecast period.
Major market player included in this report are:
Recordati Group
Eli Lilly and Company
Bristol-Myers Squibb Company
Y-mabs Therapeutics, Inc.
MacroGenics Inc.
AstraZeneca plc
United Therapeutics Corporation
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Cellectar Biosciences, Inc.
The detailed segments and sub-segment of the market are explained below:
By Type
Chemotherapy
Immunotherapy
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Online
Offline
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL NEUROBLASTOMA DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Global Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Type
2.3.2. By Route of Administration
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
CHAPTER 3. GLOBAL NEUROBLASTOMA DRUGS MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. GLOBAL NEUROBLASTOMA DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY TYPE 2022-2032
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Others
CHAPTER 6. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032
6.1. Oral
6.2. Injectable
CHAPTER 7. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022-2032
7.1. Online
7.2. Offline
CHAPTER 8. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY REGION 2022-2032
8.1. North America Neuroblastoma Drugs Market
8.1.1. U.S. Neuroblastoma Drugs Market
8.1.1.1. Type breakdown size & forecasts, 2022-2032
8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Neuroblastoma Drugs Market
8.2. Europe Neuroblastoma Drugs Market
8.2.1. U.K. Neuroblastoma Drugs Market
8.2.2. Germany Neuroblastoma Drugs Market
8.2.3. France Neuroblastoma Drugs Market
8.2.4. Spain Neuroblastoma Drugs Market
8.2.5. Italy Neuroblastoma Drugs Market
8.2.6. Rest of Europe Neuroblastoma Drugs Market
8.3. Asia-Pacific Neuroblastoma Drugs Market
8.3.1. China Neuroblastoma Drugs Market
8.3.2. India Neuroblastoma Drugs Market
8.3.3. Japan Neuroblastoma Drugs Market
8.3.4. Australia Neuroblastoma Drugs Market
8.3.5. South Korea Neuroblastoma Drugs Market
8.3.6. Rest of Asia Pacific Neuroblastoma Drugs Market
8.4. Latin America Neuroblastoma Drugs Market
8.4.1. Brazil Neuroblastoma Drugs Market
8.4.2. Mexico Neuroblastoma Drugs Market
8.4.3. Rest of Latin America Neuroblastoma Drugs Market
8.5. Middle East & Africa Neuroblastoma Drugs Market
8.5.1. Saudi Arabia Neuroblastoma Drugs Market
8.5.2. South Africa Neuroblastoma Drugs Market
8.5.3. Rest of Middle East & Africa Neuroblastoma Drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Recordati Group
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Eli Lilly and Company
9.3.3. Bristol-Myers Squibb Company
9.3.4. Y-mabs Therapeutics, Inc.
9.3.5. MacroGenics Inc.
9.3.6. AstraZeneca plc
9.3.7. United Therapeutics Corporation
9.3.8. Pfizer Inc.
9.3.9. Teva Pharmaceutical Industries Ltd.
9.3.10. Cellectar Biosciences, Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Global Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Type
2.3.2. By Route of Administration
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
CHAPTER 3. GLOBAL NEUROBLASTOMA DRUGS MARKET DYNAMICS
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
CHAPTER 4. GLOBAL NEUROBLASTOMA DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY TYPE 2022-2032
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Others
CHAPTER 6. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022-2032
6.1. Oral
6.2. Injectable
CHAPTER 7. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022-2032
7.1. Online
7.2. Offline
CHAPTER 8. GLOBAL NEUROBLASTOMA DRUGS MARKET SIZE & FORECASTS BY REGION 2022-2032
8.1. North America Neuroblastoma Drugs Market
8.1.1. U.S. Neuroblastoma Drugs Market
8.1.1.1. Type breakdown size & forecasts, 2022-2032
8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Neuroblastoma Drugs Market
8.2. Europe Neuroblastoma Drugs Market
8.2.1. U.K. Neuroblastoma Drugs Market
8.2.2. Germany Neuroblastoma Drugs Market
8.2.3. France Neuroblastoma Drugs Market
8.2.4. Spain Neuroblastoma Drugs Market
8.2.5. Italy Neuroblastoma Drugs Market
8.2.6. Rest of Europe Neuroblastoma Drugs Market
8.3. Asia-Pacific Neuroblastoma Drugs Market
8.3.1. China Neuroblastoma Drugs Market
8.3.2. India Neuroblastoma Drugs Market
8.3.3. Japan Neuroblastoma Drugs Market
8.3.4. Australia Neuroblastoma Drugs Market
8.3.5. South Korea Neuroblastoma Drugs Market
8.3.6. Rest of Asia Pacific Neuroblastoma Drugs Market
8.4. Latin America Neuroblastoma Drugs Market
8.4.1. Brazil Neuroblastoma Drugs Market
8.4.2. Mexico Neuroblastoma Drugs Market
8.4.3. Rest of Latin America Neuroblastoma Drugs Market
8.5. Middle East & Africa Neuroblastoma Drugs Market
8.5.1. Saudi Arabia Neuroblastoma Drugs Market
8.5.2. South Africa Neuroblastoma Drugs Market
8.5.3. Rest of Middle East & Africa Neuroblastoma Drugs Market
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Key Company SWOT Analysis
9.1.1. Company
9.1.2. Company
9.1.3. Company
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Recordati Group
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Eli Lilly and Company
9.3.3. Bristol-Myers Squibb Company
9.3.4. Y-mabs Therapeutics, Inc.
9.3.5. MacroGenics Inc.
9.3.6. AstraZeneca plc
9.3.7. United Therapeutics Corporation
9.3.8. Pfizer Inc.
9.3.9. Teva Pharmaceutical Industries Ltd.
9.3.10. Cellectar Biosciences, Inc.
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Neuroblastoma Drugs Market, report scope
TABLE 2. Global Neuroblastoma Drugs Market estimates & forecasts by Region 2022-2032 (USD Million)
TABLE 3. Global Neuroblastoma Drugs Market estimates & forecasts by Type 2022-2032 (USD Million)
TABLE 4. Global Neuroblastoma Drugs Market estimates & forecasts by Route of Administration 2022-2032 (USD Million)
TABLE 5. Global Neuroblastoma Drugs Market estimates & forecasts by Distribution Channel 2022-2032 (USD Million)
TABLE 6. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 11. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 16. U.S. Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 17. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 18. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 19. Canada Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 20. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 21. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 22. UK Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 23. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 24. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 25. Germany Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 26. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 27. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 28. France Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 29. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 30. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 31. Italy Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 32. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 33. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 34. Spain Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 35. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 36. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 37. RoE Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 38. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 39. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 40. China Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 41. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 42. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 43. India Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 44. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 45. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 46. Japan Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 47. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 48. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 49. Australia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 50. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 51. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 52. South Korea Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 53. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 54. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 55.
TABLE 56. RoAPAC Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 57. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 58. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 59. Brazil Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 60. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 61. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 62. Mexico Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 63. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 64. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 65. RoLA Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 66. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 67. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 68. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 69. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 70. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 71. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 72.
TABLE 73. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 74. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 75. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 76. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 77. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 78. List of secondary sources, used in the study of Global Neuroblastoma Drugs Market.
TABLE 79. List of primary sources, used in the study of Global Neuroblastoma Drugs Market.
TABLE 80. Years considered for the study.
TABLE 81. Exchange rates considered.
TABLE 1. Global Neuroblastoma Drugs Market, report scope
TABLE 2. Global Neuroblastoma Drugs Market estimates & forecasts by Region 2022-2032 (USD Million)
TABLE 3. Global Neuroblastoma Drugs Market estimates & forecasts by Type 2022-2032 (USD Million)
TABLE 4. Global Neuroblastoma Drugs Market estimates & forecasts by Route of Administration 2022-2032 (USD Million)
TABLE 5. Global Neuroblastoma Drugs Market estimates & forecasts by Distribution Channel 2022-2032 (USD Million)
TABLE 6. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 7. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 8. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 9. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 10. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 11. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 12. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 13. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 14. Global Neuroblastoma Drugs Market by segment, estimates & forecasts, 2022-2032 (USD Million)
TABLE 15. Global Neuroblastoma Drugs Market by region, estimates & forecasts, 2022-2032 (USD Million)
TABLE 16. U.S. Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 17. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 18. U.S. Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 19. Canada Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 20. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 21. Canada Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 22. UK Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 23. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 24. UK Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 25. Germany Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 26. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 27. Germany Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 28. France Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 29. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 30. France Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 31. Italy Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 32. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 33. Italy Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 34. Spain Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 35. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 36. Spain Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 37. RoE Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 38. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 39. RoE Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 40. China Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 41. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 42. China Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 43. India Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 44. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 45. India Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 46. Japan Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 47. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 48. Japan Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 49. Australia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 50. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 51. Australia Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 52. South Korea Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 53. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 54. South Korea Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 55.
TABLE 56. RoAPAC Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 57. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 58. RoAPAC Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 59. Brazil Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 60. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 61. Brazil Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 62. Mexico Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 63. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 64. Mexico Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 65. RoLA Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 66. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 67. RoLA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 68. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 69. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 70. Saudi Arabia Neuroblastoma Drugs Market estimates & forecasts, 2022-2032 (USD Million)
TABLE 71. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 72.
TABLE 73. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 74. South Africa Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 75. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 76. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 77. RoMEA Neuroblastoma Drugs Market estimates & forecasts by segment 2022-2032 (USD Million)
TABLE 78. List of secondary sources, used in the study of Global Neuroblastoma Drugs Market.
TABLE 79. List of primary sources, used in the study of Global Neuroblastoma Drugs Market.
TABLE 80. Years considered for the study.
TABLE 81. Exchange rates considered.
LIST OF FIGURES
FIG 1. Global Neuroblastoma Drugs Market, research methodology
FIG 2. Global Neuroblastoma Drugs Market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Neuroblastoma Drugs Market, key trends 2023
FIG 5. Global Neuroblastoma Drugs Market, growth prospects 2022-2032
FIG 6. Global Neuroblastoma Drugs Market, porters 5 force model
FIG 7. Global Neuroblastoma Drugs Market, pestel analysis
FIG 8. Global Neuroblastoma Drugs Market, value chain analysis
FIG 9. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 10. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 11. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 12. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 13. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 14. Global Neuroblastoma Drugs Market, regional snapshot 2022 & 2032
FIG 15. North America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 16. Europe Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 17. Asia pacific Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 18. Latin America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 20. Global Neuroblastoma Drugs Market, company market share analysis (2023)
FIG 1. Global Neuroblastoma Drugs Market, research methodology
FIG 2. Global Neuroblastoma Drugs Market, market estimation techniques
FIG 3. Global market size estimates & forecast methods.
FIG 4. Global Neuroblastoma Drugs Market, key trends 2023
FIG 5. Global Neuroblastoma Drugs Market, growth prospects 2022-2032
FIG 6. Global Neuroblastoma Drugs Market, porters 5 force model
FIG 7. Global Neuroblastoma Drugs Market, pestel analysis
FIG 8. Global Neuroblastoma Drugs Market, value chain analysis
FIG 9. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 10. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 11. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 12. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 13. Global Neuroblastoma Drugs Market by segment, 2022 & 2032 (USD Million)
FIG 14. Global Neuroblastoma Drugs Market, regional snapshot 2022 & 2032
FIG 15. North America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 16. Europe Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 17. Asia pacific Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 18. Latin America Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 19. Middle East & Africa Neuroblastoma Drugs Market 2022 & 2032 (USD Million)
FIG 20. Global Neuroblastoma Drugs Market, company market share analysis (2023)
